Aging of the Nigrostriatal System in the Squirrel Monkey

Journal of Comparative Neurology

Volumn 471, Issue 4, 2004, Pages 387-395

  McCormack, Alison L ^a,b   Di Monte, Donato A ^a   Delfani, Kioumars ^b   Irwin, Ian ^a   DeLanney, Louis E ^a   Langston, William J ^a   Janson, Ann Marie ^a,b  

^a PARKINSON S INSTITUTE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopamine; MPTP; Neuromelanin; Parkinson's disease; Stereology; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BIOLOGICAL MARKER; NEUROMELANIN; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL LOSS; CELL SUBPOPULATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FEMALE; IMMUNOREACTIVITY; INCIDENCE; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SQUIRREL MONKEY; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

AGING; ANIMALS; CELL COUNT; CORPUS STRIATUM; FEMALE; MALE; SAIMIRI; SUBSTANTIA NIGRA;

EID: 1642523445     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.20036     Document Type: Article

References (45)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
2. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. 2002. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 28:283-291.
3. Calne DB, Langston JW. 1983. Aetiology of Parkinson's disease. Lancet 2:1457-1459.
4. Dahlström A, Fuxe K. 1964. Evidence for the existence of monoamine containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brainstem neurons. Acta Physiol Scand 62(suppl 232):1-55.
5. D'Amato RJ, Lipman ZP, Snyder SH. 1986. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231:987-989.
6. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston JW. 2000. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15:459-466.
7. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH. 1998. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401:253-265.
8. Fearnley JM, Lees AJ. 1991. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301.
9. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM. 2002. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80:68-77.
10. Gibb WR, Lees AJ. 1991. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54:388-396.
11. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
12. Gundersen HJ, Jensen EB. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263.
13. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR Jr, Felten DL. 1986. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 70:326-331.
14. Herrero MT, Hirsch EC, Kastner A, Luquin MR, Javoy-Agid F, Gonzalo LM, Obeso JA, Agid Y. 1993a. Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. Dev Neurosci 15:37-48.
15. Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J, Javoy-Agid F, Obeso JA, Agid Y. 1993b. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 56:499-511.
16. Hirsch EC, Graybiel AM, Agid Y. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
17. Irwin I, Ricaurte GA, DeLanney LE, Langston JW. 1988. The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age. Neurosci Lett 87:51-56.
18. Irwin I, Finnegan KT, DeLanney LE, Di Monte DA, Langston JW. 1992. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP inC57BL/6 mice: a critical reassessment. Brain Res 572:224-231.
19. Irwin I, DeLanney LE, McNeill T, Chan P, Forno LS, Murphy GM Jr, Di Monte DA, Sandy MS, Langston JW. 1994. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3:251-265.
20. Irwin I, Delanney L, Chan P, Sandy MS, Di Monte DA, Langston JW. 1997. Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice. Neurobiol Aging 18:235-241.
21. Jarvis MF, Wagner GC. 1985. Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neuropharmacology 24:581-583.
22. Jellinger KA. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14:115-140.
23. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. 1992. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 59:1080-1089.
24. Kilpatrick I, Jones M, Phillipson O. 1986. A semiautomated analysis method for catecholamines, indoleamines and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876.
25. Krauth J. 1988. Distribution-free statistics: an application oriented approach. Amsterdam: Elsevier.
26. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC. 2000. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123:366-373.
27. Lowry OH, Rosebrough JJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin reagent. J Biol Chem 193:265-275.
28. Ma SY, Roytt M, Collan Y, Rinne JO. 1999. Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 250:394-399.
29. Mann DM, Yates PO. 1983. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 21:193-203.
30. McGeer PL, McGeer EG, Suzuki JS. 1977. Aging and extrapyramidal function. Arch Neurol 34:33-35.
31. Muthane U, Yasha TC, Shankar SK. 1998. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 43:283-287. Ovadia A, Zhang Z, Gash DM. 1995. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 16:931-937.
32. Pakkenberg H, Andersen BB, Burns RS, Pakkenberg B. 1995. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res 693:201-206.
33. Reeves S, Bench C, Howard R. 2002. Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry 17:359-370.
34. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. 1987a. Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26:97-99.
35. Ricaurte GA, Irwin I, Forno LS, DeLanney LE, Langston E, Langston JW. 1987b. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403:43-51.
36. Rose S, Nomoto M, Jackson EA, Gibb WR, Jaehnig P, Jenner P, Marsden CD. 1993. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 230:77-85.
37. Tanner CM, Goldman SM. 1996. Epidemiology of Parkinson's disease. Neurol Clin 14:317-35.
38. Terr LI. 1986. Demonstration of lipofuscin and Nissl bodies in crystal violet stained sections using a fluorescence technique or pyronin Y stain. Stain Technol 61:309-313.
39. Walsh SL, Wagner GC. 1989. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. Synapse 3:308-314.
40. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. 1999. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with non-toxic doses of MPTP. Exp Neurol 156:62-70.
41. Wenk GL, Pierce DJ, Struble RG, Price DL, Cork LC. 1989. Age-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging 10:11-19.
42. Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid BS, Satyamurthy N, DeLanney LE, Togasaki DM, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR. 2001. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Dis 16:838-848.
43. Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. 2001. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 54:414-418.
44. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. 2002. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 510:216-220.
45. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.